论文部分内容阅读
目的：探讨非洋地黄类强心药物在治疗慢性阻塞性肺病（ＣＯＰＤ）并肺原性心脏病（肺心病）心功能不全中的作用，以便选择更理想的药物应用于临床。方法：观察多巴酚丁胺和参麦注射液对慢性缺氧鼠心输出量、肺循环与体循环血流动力学的影响。结果：与葡萄糖注射液对照组相比，多巴酚丁胺和参麦注射液在增加心输出量的同时降低外周血管压力和阻力，对体循环的作用要大于对肺循环的作用；参麦注射液降低肺／体动脉压比为０．５７±０．０７，降低肺／体循环阻力比为０．８２±０．０８；多巴酚丁胺降低肺／体动脉压比为０．３６±０．０４，降低肺／体循环阻力比为０．６３±０．０９；相比而言，参麦注射液对肺循环的作用要较多巴酚丁胺好。结论：多巴酚丁胺和参麦注射液均可改善慢性缺氧鼠的心功能和肺血流动力学，参麦注射液在选择性降低肺动脉压和肺循环阻力、增加心输心量方面显示出较好效果，因而在治疗ＣＯＰＤ并发肺动脉高压、肺心病和心功能不全方面有一定应用价值。
Objective: To investigate the role of non-digitalis cardiac drug in the treatment of chronic obstructive pulmonary disease (COPD) and pulmonary heart disease (pulmonary heart disease) cardiac insufficiency in order to choose a more ideal drug for clinical use. Methods: The effects of dobutamine and shenmai injection on cardiac output, pulmonary circulation and systemic hemodynamics in chronic hypoxia rats were observed. RESULTS: Dobutamine and Shenmai injection decreased peripheral pressure and resistance while increasing cardiac output, and had a greater effect on systemic circulation than pulmonary perfusion. Shenmai injection The lung-to-body arterial pressure ratio was decreased to 0.57 ± 0.07, and the lung / body resistance ratio was decreased to 0.82 ± 0.08. Dobutamine reduced the lung / body pressure ratio to 0.36 ± 0. 04, reducing the lung / systemic resistance ratio was 0.63 ± 0.09; in contrast, Shenmai injection on the role of pulmonary circulation to be more good thanbutamine. Conclusion: Both dobutamine and Shenmai injection can improve cardiac function and pulmonary hemodynamics in rats with chronic hypoxia. Shenmai injection can selectively decrease pulmonary arterial pressure and pulmonary circulation resistance and increase cardiac output A better effect, and therefore in the treatment of COPD complicated by pulmonary hypertension, pulmonary heart disease and heart failure have a certain value.